VNRX · Volitionrx Ltd
$0.54
-0.09 (-14.78%)
At close · Aug 14
View the 10-K filed Mar 31, 2026
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company concluded that these plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
Customer concentration
— top 2 customers 38% of receivables
2 customers — 38% of receivables (December 31, 2025)
“At December 31, 2025 the two largest customer balances represented over 38% of the total outstanding accounts receivable balance.”
Market Cap
$7.34M
Shares
13.65M
Volitionrx Ltd Earnings Call Transcripts
Every quarterly earnings call for Volitionrx Ltd (VNRX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲28.4%
$32,714
−$7.81M
'22 Q3
22-11-14
▲740.7%
$119,715
−$7.34M
'22 Q4
23-02-21
▲31.2%
$149,808
−$8.87M
'23 Q1
23-05-10
▲444.1%
$216,310
−$9.55M
'23 Q2
23-08-14
▲405%
$165,211
−$8.45M
'23 Q3
23-11-14
▲103.8%
$243,973
−$8.80M
'23 Q4
24-03-25
▲14.5%
$171,535
−$8.37M
'24 Q1
24-05-13
▲83%
$395,797
−$6.99M
'24 Q2
24-08-14
▲187.2%
$474,522
−$5.82M
'24 Q3
24-11-14
▼21.4%
$191,657
−$5.79M
'24 Q4
25-03-31
▲43.6%
$246,385
−$5.42M
'25 Q1
25-05-15
▲2.8%
$406,688
−$6.28M
'25 Q2
25-08-14
▲32.2%
$627,277
−$5.38M
'25 Q3
25-10-14
▲133.2%
$447,034
−$6.27M
'25 Q4
26-04-01
▲299.8%
$985,076
−$6.66M
'26 Q1
26-05-15
LATEST
▼2%
$398,657
−$7.33M
'26 Q2
26-08-14
Earnings call
FY26 · Q2
2026-08-14
Volitionrx Ltd Q2 FY2026 Earnings Call
Revenue
$398,657
▼ 2% YoY Diluted EPS
$-0.85
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-15
Volitionrx Ltd Q1 FY2026 Earnings Call
Positive tone
Licensing and commercialization
Capture-C pipe
Financial position and cost control
Revenue
$985,076
▲ 299.8% YoY Diluted EPS
$-0.97
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-04-01
Volitionrx Ltd Q4 FY2025 Earnings Call
Confident tone
Nu.Q Cancer and sepsis clinical use / real-world deployment
Capture-Seq / liquid biopsy platform
Human licensing strategy and partnerships
Revenue
$447,034*
▲ 133.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-14
Volitionrx Ltd Q3 FY2025 Earnings Call
Positive tone
Werfen APS Licensing Agreement
Capture-Seq Liquid Biopsy Technology
Hologic Diagenode Co-Marketing Agreement
Revenue
$627,277
▲ 32.2% YoY Diluted EPS
$-1.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Volitionrx Ltd Q2 FY2025 Earnings Call
Confident tone
Revenue growth and first human product sales
Nu.Q NETs sepsis and disease applications
Taiwan screening program implementation
Revenue
$406,688
▲ 2.8% YoY Diluted EPS
$-1.22
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Volitionrx Ltd Q1 FY2025 Earnings Call
Confident tone
Human diagnostics commercialization
Sepsis / Nu.Q NETs pillar
Licensing deals and partnerships
Revenue
$246,385
▲ 43.6% YoY Diluted EPS
$-1.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Volitionrx Ltd Q4 FY2024 Earnings Call
Revenue
$191,657*
▼ 21.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Volitionrx Ltd Q3 FY2024 Earnings Call
Confident tone
Sepsis and Innovation Lab
Lung Cancer Diagnostics
Feline Test Development
Revenue
$474,522
▲ 187.2% YoY Diluted EPS
$-1.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Volitionrx Ltd Q2 FY2024 Earnings Call
Positive tone
Human oncology licensing pursuit
Sepsis program (Nu.Q NETs / H3.1)
Cost reduction program
Revenue
$395,797
▲ 83% YoY Diluted EPS
$-1.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Volitionrx Ltd Q1 FY2024 Earnings Call
Positive tone
Nu.Q NETs and Sepsis clinical data
Capture-PCR and platform adaptability
Non-dilutive funding pursuit
Revenue
$171,535
▲ 14.5% YoY Diluted EPS
$-2.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-25
Volitionrx Ltd Q4 FY2023 Earnings Call
Positive tone
Human Sepsis - Nu.Q NET and Capture-PCR
Financial Position and Cash Runway
Human Licensing Deals Pipeline
Revenue
$243,973*
▲ 103.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
Volitionrx Ltd Q3 FY2023 Earnings Call
Revenue
$165,211
▲ 405% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Volitionrx Ltd Q2 FY2023 Earnings Call
Revenue
$216,310
▲ 444.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Volitionrx Ltd Q1 FY2023 Earnings Call
Revenue
$149,808
▲ 31.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-21
Volitionrx Ltd Q4 FY2022 Earnings Call
Revenue
$119,715*
▲ 740.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Volitionrx Ltd Q3 FY2022 Earnings Call
Revenue
$32,714
▲ 28.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Volitionrx Ltd Q2 FY2022 Earnings Call
Revenue
$39,752
▲ 60.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Volitionrx Ltd Q1 FY2022 Earnings Call
Revenue
$114,211
▲ 347.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-30
Volitionrx Ltd Q4 FY2021 Earnings Call
Revenue
$14,240*
▲ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Volitionrx Ltd Q3 FY2021 Earnings Call
Revenue
$25,483
▲ 4331.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Volitionrx Ltd Q2 FY2021 Earnings Call
Revenue
$24,782
▲ 377.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Volitionrx Ltd Q1 FY2021 Earnings Call
Revenue
$25,530
▲ 4593% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-22
Volitionrx Ltd Q4 FY2020 Earnings Call
Revenue
$7,120*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
Volitionrx Ltd Q3 FY2020 Earnings Call
Revenue
$575
▼ 96.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-13
Volitionrx Ltd Q2 FY2020 Earnings Call
Revenue
$5,194
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Volitionrx Ltd Q1 FY2020 Earnings Call
Revenue
$544
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-20
Volitionrx Ltd Q4 FY2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls